publication date: Dec. 19, 2010

In this issue: 

Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge?

John Niederhuber named NCI chief operating officer; the surgeon was asked to leave two previous positions.

Cancer death rate dropping 1.1 percent a year, annual report finds.

Download (PDF 1016KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.